Oncoinvent issues share options to new CMO
Oslo-based Oncoinvent ASA has awarded 20,000 share options to its newly appointed Chief Medical Officer, Dr. Zuzana Jirakova Trnkova.
Oncoinvent ASA has initiated a long-term incentive grant for its new Chief Medical Officer, Dr. Zuzana Jirakova Trnkova, involving 20,000 share options. The options were set with a strike price of NOK 67.35, a figure determined by the volume-weighted average share price recorded on the final trading day prior to the grant.
Each option grants the right to acquire one ordinary share in the company upon exercise. This issuance represents the total current holdings for Dr. Trnkova following her recent appointment to the executive leadership team.
The equity grant follows standard corporate incentive practices used to align executive interests with long-term shareholder value. The company, which specializes in radiopharmaceutical development, continues to adjust its leadership compensation structure as it advances its clinical pipeline.